Led · Series C · Mar 2026

Cognito Therapeutics is a clinical-stage neurotechnology firm focused on creating neuroprotective, non-invasive therapies for central nervous system disorders. Its lead product, Spectris, is an at-home therapeutic platform that delivers sensory-driven neurostimulation to synchronize neural activity across interconnected brain networks. Feasibility studies indicate Spectris may preserve cognition, maintain daily function, and slow brain atrophy in patients with mild-to-moderate Alzheimer’s disease. The company plans to expand the Spectris platform into additional neurodegenerative indications through a network of brain-health collaboratories, beginning with the WVU Rockefeller Neuroscience Institute. Proceeds from its latest financing will fund these clinical expansions and further platform development. Although specific revenue or user numbers were not disclosed, the company positions itself as a late clinical-stage player nearing pivotal trials.

Participated · Series A · Oct 2025

Ampa develops the Ampa One, an FDA-cleared, portable transcranial magnetic stimulation (TMS) system designed for simplicity and scalability. The company says the device fits in the trunk of a car, costs $3,000 per month, can be operated after a few hours of training, and features a lightweight hand-holdable coil, camera-guided targeting, and pre-printed neuronavigation caps. Ampa reports the Ampa One is already in use at clinics across more than 30 U.S. states and that demand has doubled every quarter. The company secured regulatory approval in Israel and plans commercial launch overseas. Leadership cited in the announcement includes co-founder Jonathan Downar, MD, PhD, and CEO Don Vaughn, PhD. Ampa positions the product as a lower-cost, higher-throughput option for clinics and is using recent financing to accelerate rollout and meet accelerating demand.

Participated · Series B · Mar 2025

Accro Bioscience is a clinical-stage biotech developing first- and best-in-class small-molecule therapeutics that target regulatory cell death pathways for inflammatory and immune-mediated diseases. Its lead asset, AC-101, is a selective RIPK2 inhibitor being developed for moderate-to-severe ulcerative colitis and has completed Phase I studies in healthy volunteers in Australia and China, plus a Phase Ib/IIa proof-of-concept study in Chinese patients. The company has received IND clearance from the U.S. FDA to proceed with Phase II studies of AC-101. Accro announced a $50 million Series C to fund a Phase IIb trial of AC-101 and to advance other pipeline candidates. The company operates out of New York and Suzhou and describes a multi-asset pipeline originating from a proprietary drug discovery platform focused on regulatory cell death and inflammation. Ongoing clinical progress and the new financing position Accro to advance global development of its lead and follow-on programs.

Participated · Series C · Jan 2025

Geneoscopy leverages a proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform to develop diagnostic tests for gastrointestinal diseases. Its lead product, ColoSense, is an FDA-approved at-home, stool-based colorectal cancer screening test for average-risk individuals over age 45. The company pairs its RNA isolation platform with Bio-Rad’s Droplet Digital PCR (ddPCR) technology to achieve high sensitivity and specificity. Geneoscopy plans to launch and commercialize ColoSense and is working with Labcorp to provide broad availability so providers can order the test within screening programs. The firm is also investing in an innovative pipeline of diagnostic tests for inflammatory bowel disease, including tools for treatment selection and therapy monitoring. The recent financing is positioned to support commercialization, regulatory milestones, and continued product development. Geneoscopy is a St. Louis, MO–based life sciences company focused on developing diagnostic tests for gastrointestinal health. Its lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. The device was awarded Breakthrough Device Designation from the US FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Preliminary trials suggest the diagnostic can detect these lesions at a higher rate than existing noninvasive screening tests. The company intends to use recent funding to support the U.S. CRC-PREVENT pivotal trial, scale commercial infrastructure, and expand its diagnostic product pipeline. Andrew Barnell is the company's CEO. Geneoscopy is a life sciences company focused on developing diagnostic tests for gastrointestinal (GI) health. Its lead product is a colorectal cancer (CRC) screening test that quantifies eukaryotic RNA isolated from epithelial cells in stool to detect CRC and advanced adenomas. The company announced an oversubscribed $6.9 million Series A and plans to use the proceeds to advance the CRC screening test. The financing was led by Cultivation Capital and NT Investments, with Lightchain Capital LLC as a significant investor. Following the round, Bobby W. Sandage, Jr., Najeeb Thomas, and Drew Dennison are joining Geneoscopy’s board of directors. Geneoscopy highlights that stool-derived eukaryotic RNA biomarkers are highly sensitive for both cancer and precancerous lesions, and it intends to pursue other applications of its platform technology.

Participated · Equity · Sep 2024

F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat invasive fungal infections. The company discovered the orotomide class, which selectively targets a key enzyme in the de novo pyrimidine biosynthesis pathway. Its lead candidate, olorofim, is the first orotomide antifungal and an oral therapy with a mechanism distinct from existing antifungal classes. Olorofim has been awarded Breakthrough Therapy Designation by the FDA for multiple indications and is intended for serious invasive or rare fungal diseases where current treatments are inappropriate or ineffective. F2G plans to use the recent financing to complete late-stage development, seek regulatory approval, and prepare for U.S. commercialization of olorofim. Led by CEO Francesco Maria Lavino, the company operates in the UK, US, and Austria and has a 100%-owned subsidiary in Austria. F2G Ltd is a Manchester, UK-based clinical-stage biopharmaceutical company focused on discovery and development of novel therapies to treat potentially life‑threatening invasive fungal infections. Its lead asset is olorofim, a novel oral antifungal from a new class called the orotomides that selectively targets a key enzyme in the de novo pyrimidine biosynthesis pathway. Olorofim is in a Phase 2b open‑label study (NCT03583164) for patients with limited treatment options for invasive aspergillosis and other rare mold infections. F2G raised $70M in financing to advance late‑stage development and US commercialization of olorofim. The round was co‑led by new investors Forbion and Sofinnova Partners, with participation from existing backers including Novo Holdings, Morningside Ventures, Cowen Healthcare Investments and Advent Life Sciences. Nanna Lüneborg (Forbion) and Joe Anderson (Sofinnova Partners) will join the F2G board. In May 2022 the company entered a $480M strategic collaboration with Shionogi to develop and commercialize olorofim in Europe and Asia, which included $100M upfront, $380M in regulatory and commercialization milestones, and double‑digit royalties on sales. F2G operates in the UK, US and Austria and is led by CEO Francesco Maria Lavino. F2G discovers and develops antifungal therapies, including a new class of agents called the orotomides that target DHODH (dihydroorotate dehydrogenase). Its lead candidate, olorofim, is a novel antifungal in a Phase 2b open-label study focused on rare and resistant invasive fungal infections. Olorofim has been granted Breakthrough Therapy designation by the FDA (November 2019), the only antifungal to receive that status based on early tolerability and efficacy data. The company is advancing late-stage clinical programs and preparing for commercialisation. Proceeds from the recent financing will fund those clinical programs and organisational scale-up. Ian Nicholson is CEO of the company. F2G is a Manchester-based biotech focused on discovering and developing antifungal drugs. It is advancing F901318, a novel clinical-stage candidate for the treatment of invasive aspergillosis and other serious rare mould infections. The company planned a small PK Phase 2 clinical trial for F901318 in the second half of 2016 and aimed to begin pivotal registration trials for invasive aspergillosis in the first half of 2017 via an accelerated regulatory pathway. F2G raised $60M in financing led by Sectoral Asset Management to support development of its pipeline. Investors in the round include Novo A/S, Aisling Capital, Brace Pharma Capital and existing backers Advent Life Sciences LLP, Novartis Venture Fund, Sunstone Capital and Merifin Capital. Dr Maha Katabi and Dr Martin Edwards are joining the board as part of the financing, and Ian Nicholson serves as CEO.